Fighting Patient's Right to Grow - A Look at the Allard Case



The 2000 decision in R v. Parker held that individuals with a medical need had the right to possess cannabis for medical purposes.  This decision brought in the MMAR regulations which allowed patients to grow their own medicine rather than purchase from the one designated supplier at the time.

However, in 2013, Health Canada announced new regulations for medical cannabis that was to replace the previous MMAR regulations and which eliminated the right for patients to grow their own. These new regulations resulted from our Canadian BC neighbors stepping up and persevering all the way to the Supreme Court for our charter right to consume cannabis medicine rather than be limited to its dried plant form.

In 2014, the MMPR regulations took effect which required all personal growers under the previous MMAR regulations to cease and desist -growing their own plant based medicine.

The new MMPR regulations required patients to order their medicine (sight unseen) from commercial growers that have been licensed by Health Canada as a Licensed Producer (LP). These new regulations were put into effect after Health Canada lost when the MMAR - then MMPR regulations were challenged on the basis that it limited cannabis use to only that in dried form. In other words, patients were legally denied ingesting the medicine in its most effective form and it remained illegal to produce effective RSO (Rick Simpson Oil) to reverse cancer,

By transferring the right to grow medical cannabis out of the patient's hands and into large conglomerates that operate for profit, contravenes patients charter rights and the regulations put forward by Health Canada demonstrate a gross miscarriage of their duty to help Canadians improve their health - their stated mandate - reason to be.

The first challenge of the MMPR was the case of R. vs. Smith in which the MMAR was initially challenged (which then turned into the MMPR)  as unconstitutional since it limited medical use of cannabis to only that in its dried form. This restriction forces patients to chose between a legal but inadequate treatment and that of an illegal but more effective one (smoking was permitted as a complementary medicine BUT ingesting the plant in its most effective form was illegal - because it replaces conventional medicine?)

Despite Health Canada's inadequacy in meeting their stated mission of improving the health of Canadians, their new regulations - MMPR - severely restricted access to the medicine and reduced the quantity allowed to a level that makes it impossible to produce effective oral medication needed for severe diseases.

The second challenge involving the MMPR and charter rights infringement was Allard et al v. Canada. At issue in this case was the violation of charter rights and the MMPR as these regulations do not guarantee the necessary quality, strain and quantity being available under the single source system that Health Canada devised with the LP concept. In other words, at issue in this case was the right to grow.

 Health Canada contended that concerns about the MMAR led the government to reform those regulations.  The concerns raised by Health Canada at trial were found to be invalid as they had no evidence to support the claims they made which included: home growers became ill from their crop (since the plant was not being controlled in a corporate environment?); the public safety issues reported including residential fires and residential theft - which were unsupported with evidence and the claims of harm arising from fertilizers and other chemicals used on the medicine and not controlled. Obviously no evidence could be supplied for this latter claim as no home grower would dream of using harmful chemicals on this plant.

A charter infringement raised by the plaintiffs was that even though the government would reap big benefits under the new regime in terms of cost savings, those patients in need of the medicine would be greatly impacted with increased costs.

A contended issue of Health Canada involved their concern with medically appropriate dosages since overdosing is pursuant to over-prescribing and these are a serious problem as seen with prescription pain pills. This was despite expert witnesses testimony to the contrary. Also an expert witness for Health Canada,  from the Netherlands stated that there are no medical indications for using cannabis in excess of 5 grams per day.

Another witness for HC was Dr. Daeninck who asserted that the College of Family Physicians of Canada agreed that 1 - 3 grams per day was medically sufficient, although no evidence was provided in support of those claims.  This author found his assertion suspect since the College has continually contended that there was a lack of significant scientific evidence to support its use and should their member doctors decide to prescribe it, they were advised to assert that it was only after all conventional therapies were attempted but ended up being unsuccessful.

Dr. Harold Kalant, MD, PhD, another witness for the Defense, a researcher with U of T in Alcohol and Drug Abuse, argued that no scientific evidence exists that supports a specific method of consumption as being more effective in treating a particular condition. He further asserted that he was unable to find a single scientific study comparing the therapeutic effects of dried cannabis to that of ingesting it orally. (Seriously?)                                    

In much the same vein as the issue of consumption, it was argued that lack of scientific research exists relating to specific medicinal uses of different strains.  Dr. Kalant, the Defendant's witness, agreed that although different strains may have different chemical compositions, the lack of scientific research does not support whether different strains have different medicinal effects for various illness suffered by patients. He further questioned whether the large number of the 'so-called' strains advertised on the internet, are in fact strains as defined botanically. He stated that the alleged medical efficacy of particular strains is not backed by clinical testing or scientific research but instead they are based either on subjective anecdotal reports or promotional advertising by producers.






The expert witnesses presented by Health Canada, the defense, continually testified at the lack of scientific evidence that exists on cannabis and the lack of dosage guidelines - all which boils down to those purporting to be authoritative on a plant in which their 'professional opinion' is opined on previous research that has since been proven wrong, have no authority on a plant they know nothing about.

Although what we are told is 'conventional medicine' - basically all the pharmaceutical pills, are supposedly scientifically proven as effective, clinically trialed and scientifically peer reviewed, as being effective.

The title to this blog should  be "Big Pharma Disrupted (or Interrupted?) since the claim for their manipulated scientifically proven medicine does not stand up to anecdotal evidence - that which is based on continual observation of fact.

As an aside:

The number of patents filed by GW Pharma in the UK and the University of Mississippi in the US (two organizations allowed to grow, study and own the findings in the cannabis plant) are extensive and include the cannabinoids CBC, CBG and THCV along with terpenes in the treatment of numerous diseases and disorders including cancer, inflammatory diseases, intestinal and/or gut disorders, Crohn's, ALS, MS, ADHD, mood disorders such as bipolar, schizophrenia, Alzheimer's, PTSD, depression, anxiety and more.

Unpublished Cannabis Research at the United Nations

RESPECT SCIENCE RE-SCHEDULE CANNABIS


In reviewing the minutes to a 1971 United Nation 'symposium' discussing the research surrounding the chemistry and biological activity of cannabis, the following was noted:

Cannabis research at the Division of Narcotic Drugs, United Nations, Geneva is mandated with the primary function of internationally coordinating cannabis research in order to avoid unnecessary duplication of effort.

The research on cannabis was to focus on "to elucidate the effects of the compounds responsible for the psychoactive effects of cannabis in man, to quantify the constituents or their metabolites in biological fluids, to determine their toxicity and side effects and to correlate these data with the social effects of the drug."

The minutes are very interesting (clickable above) as it was stated at this meeting in 1971 that the three main cannabinoids in cannabis are THC, CBN and CBD.  As a result, almost 40 years later and mountains of research later, THC and CBD are the only two cannabinoids that the cannabis industry (legislators) seem to feel are the only cannabinoids patients need to be concerned with. This is NOT in patient's best interest!

The 'authoritative' experts speaking on cannabis  at this 1971 symposium, all purported to be experts on cannabis. However, subsequent to the publications that many of these 'experts' relied upon for their reports, ignored the fact that using gas chromatography, misidentified cannabichromene (CBC) as cannabidiol (CBD). 

Opinions, please! 





Canada's Task Force on Cannabis and Bill C-45


Former Public Safety Minister Anne McLellan is said to be in charge of Canada's new task force on recreational marijuana. Ms McLellan will be reporting to a former Toronto Chief of Police, Bill Blair, in charge of the file.

What was disturbing to a medical cannabis patient was learning when Ms McLellan was the Minister of Health, in 2002 she felt “a certain degree of discomfort” around the issue of medical marijuana. She said “the courts took us down a certain path,” arguing it was not her government ’s choice to allow the use of cannabis for medical purposes.

What can Canadians expect from a task force on cannabis headed by the very person that was against legislation for the use of cannabis for medical purposes in the first place?

More than a year after this appointment, the Honourable A. Anne McLellan admitted that the courts have helped push the government into accepting the huge amount of experiential evidence heard
attesting to the important therapeutic benefits in cannabis - in the various forms and doses personally chosen.

The task force faced certain contentious issues that Ms. McLellan revealed as follows:

Medical:
The Canadian Medical Association felt quite strongly that a separate medical cannabis regime was not necessary under an 'adult cannabis user system'. However, the task force recommended that a separate regime be maintained for at least another five years, before a thorough review can be made.

Personal Cultivation:
The task force recommended that personal cultivation, strictly for personal use only, be limited to around four plants at a maximum height of 100cm

In terms of international treaty obligations, Ms McLellan stated that legalizing cannabis, along with regulating and licensing it, complies with the spirit of the international drug control treaties since the treaties speak to fairness, justice and public health . The perceived objectives of these treaties include the protection of youth and young people including keeping them out of criminal situations. 

The task force has lead to  Bill C-45 - Cannabis Act - First reading in Parliament

The THC to CBD Ratio - Inappropriate in Medicine


Although a number of cannabinoids have been identified and synthesized, why are we limited to only knowing the percentage of THC and CBD in a strain?

History of Cannabinoid Discovery:

Cannabinol or CBN, the degraded form of THC, was first identified around the end of the 19th century. The presence and quantity of this cannabinoid in your medicinal cannabis, is an indication of its age. Although mildly psychoactive, it does contain a number of medicinal benefits that contribute to homeostasis in your body.

Moving forward to the forties:

Roger Adams, the University of Illinois Department Head of Chemistry, identified CBD (Cannabidiol) in 1940 and subsequently, THC in 1942.  Despite these discoveries, it wasn't until the early sixties when these cannabinoids were fully understood and able to be synthesized (reproduced in the lab). During this time in the sixties, a number of other cannabinoids were discovered including cannabigerol (CBG), cannabichromene (CBC),Tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV).

With the adoption and implementation of the UN's  1961 Single Convention on Drugs, the United Nation's Office on Drugs and Crime (UNODC) published recommendations for the identification and analysis of confiscated 'pot' which used Gas Chromatography as the method for separating like compounds in an organic sample along with purporting that the ratio of THC to CBD was an agreed method of distinguishing drug type from fiber type marijuana. If the result of dividing THC/CBD is greater than 1, it is evidence that the plant is drug type, however, if the result is less than or equal to 1, the UN deemed the plant to be fiber-type.

The adoption by the UN of  the two distinct chemotype/phenotype varieties of cannabis as drug-type or fiber-type was the result of a number of paid studies by the UN. In 1971, Fetterman, et al, using gas chromatography, argued that their research showed that the most abundant cannabinoids present in the leaves and buds of cannabis were THC and CBD.

During the seventies, after the adoption of the UN Single Convention on Drug Abuse and the UN's recommended method of distinguishing Drug-type from Fiber-type 'marijuana', it was uncovered that CBC had been misidentified as CBD due to the separation and retention problems using Gas Chromatography as the method to separate and identify chemicals in an organic sample.

Using the ratio of THC:CBD as the method to distinguish drug type from fiber type is inherently flawed and has no place in medicine, let alone forensics. The use of this ratio and the complete oversight of the other valuable compounds in the cannabis plant, not only obscures the distinction of hemp from the medicine, it ensures that hemp remains under strict control.

The cannabinoid CBD is unique in its effectiveness for treating childhood epilepsy, the other important cannabinoids CBC, CBG and THCV should not be overlooked in choosing your medicine as these cannabinoids are extremely important in the treatment of many serious conditions and diseases.

In order that patients and customers are not limited to knowing just the quantity of THC and CBD in various cannabis strains, it is necessary to demand the full strain fingerprint, including all cannabinoids and terpenes. It is only when the full fingerprint is known, are you able to better and more intelligently choose the cannabis strain that is right for you. 



The Race for Weed is Greed - learn the facts

confused image
Confused?


As the new 'Medical Marijuana' industry emerges, there is so much conflicting information about this plant's safety and efficacy, not to mention the controversy preceding it and still surrounding it, it becomes absolutely astounding, let alone confusing to decipher the array of contradicting information. How do we reconcile all this information out there? Who can we trust for the truth? Why does the government classify information?

In 1961, the United Nations introduced the Single Convention on Drug Control, an international treaty requiring signatory members to adopt and implement similar legislation including, against the cannabis plant, This entailed treating all forms of cannabis as a dangerous drug. The UN continues to state that cannabis has no recognized or known medical use and it carries a high potential risk for abuse. Consequently, to conform to society and per 'Blue Ribbon' reports, most, if not all countries conformed to eradicating the cannabis plant, including its industrial hemp cousin.

Would it come as a shock to learn that prior to the adoption of the International Treaty - Single Convention on Drugs, and up until now, both the US government, through their Ole Miss medical marijuana lab, and the British government, through their GW Pharma research lab, have continuously filed patents on the various health benefits they discovered in the cannabis plant?

To understand the emerging medical marijuana market today, and why only two out of hundreds of cannabinoids are being sold in the new market, requires an understanding of how those two cannabinoids came to dominate. 

After the UN created the Single Convention on Narcotic Drugs, the UNODC emerged. The UNODC is an acronym for the United Nations Office on Drug Control. The UNODC, since the Single Convention treaty, has issued their publication: Recommended methods for the identification and analysis of cannabis and cannabis products

The above link will take you to a new tab and is the 2009 edition of the UNODC's latest publication on the subject. Since the creation of the Single Convention, drug analysis labs have been taught to use the ratio of THC to CBD as a reliable method for determining drug-type weed from fiber-type weed. Just as archaic then, the method for separating the compounds in a sample of pot was and still is gas chromatography.

The problem behind the use of gas chromatography as a method of separating compounds in a sample of cannabis, was in the separation of cannabidiol, CBD, from cannabichromene, CBC - it wasn't able to!

The emerging 'marijuana' market today, is still only focused on disclosing the quantity of THC to CBD, as if those are the only two cannabinoids in the plant. 

The following link is to a kindle book that can provide you with additional information:



 Cannabinoids and Terpenes kindle link

Cannabis Medicine

Cannabis Medicine book link to Amazon
Click Image for More Info
Medical cannabis is more than just the ratio of THC:CBD - the two cannabinoids that dominate what the media allows us to otherwise know about this valuable healing plant.

Digging deeper, the ratio of THC to CBD began when the United Nations Office on Drugs and Crime (UNODC) determined that this ratio was the standardized and acceptable way to determine drug-type pot from industrial-type pot. 

Cannabis, also called marijuana, became under international control and deemed one of the most dangerous drugs, with no known medical use and with the greatest potential for abuse.

Cannabis Medicine - What You Need to Know by Ryder Management Inc. provides a history of this very valuable medicinal plant along with a description of its compounds, the plant's benefits, a review of the numerous patents on this plant's medicinal qualities, recipes, and decarbing temperatures for various methods of activating the cannabinoids.

Although the government used gas chromatography as the method for separating the cannabinoids in cannabis, recommended by the United Nations, this method, as it was later revealed, erroneously grouped the cannabinoid CBC - cannabichromene with the cannabinoid - CBD -cannabidiol - which may have given CBD unnecessary and misdirected fame for what may actually be owed to CBC. 


Known Cancer Cures: Cancer Cures Revisited

Available for free as a download on Amazon Kindle, Saturday, Sep 6/14 Despite what the FDA says, download this eBook and see for yourself, the common denominator in all cancer cures ....

FDA Partial Cannabis Patent




Cannabis dosing in the 1800's

Cannabis dosing in 1800 image
USP 1936 pg 155


The above is what appeared in the United States Pharmacopoeia in 1936, just before it was made a dangerous drug under international control to make way for the emerging Petro-Pharmaceutical industry.




Terpenes and Cannabinoids in Cannabis

Terpenes and Cannabinoids in Cannabis

amazon book link for Cannabinoids and Terpenes by RyderMgt
Click Image

Ryder Management Inc. has just published another Kindle  e-Book by an "indie" author.  The book is entitled "Cannabinoids and Terpenes: The Medicinal Benefits of Cannabis" and is available only at Amazon Kindle, worldwide.  

A number of passages come to mind from this book.  One in particular follows:

" CBD - cannabidiol, a cannabinoid, found in Indica,  is a 5-HT1A receptor agonist.  5-HT1A receptors are a subset of 5-HT serotonin receptors.  Effects of the 5-HT receptors that have been observed in scientific research include decreased aggression, increased sociability, decreased sociability, decreased impulsiveness, prolonged REM sleep, reversal of opioid induced respiratory depression and facilitation of sex drive and arousal.  Activation of the 5-HT1A receptors have been involved in the "mechanism of action" in certain psycho pharmacology medications including anxiolytic, antidepressants and anti-psychotic pills.  This explains how "smoking a joint" can "take the edge off".  With this information in mind, why do some from the scientific community claim that cannabis creates the very condition it helps?"


This book's description follows:


"In addition to discussing the medicinal benefits of cannabis, more specifically the cannabinoids and terpenes; this book also looks at cannabis test kits that can be used at home for identifying cannabinoids and terpenes in cannabis samples. The synergy effect of cannabinoids and terpenes found in cannabis offer a great deal of additional benefits which is only beginning to be investigated. As patients become more educated on the full potential of cannabis preparations and with the complexities in the various compounds found in cannabis, they will become more discerning in choosing their medicine which will help increase the quality of the medication available to them and the research relating to the synergy benefits found in both cannabinoids and terpenes".